- Website: Bioavailability Challenge 2014
It is a well-established principal that even the most promising API, monoclonal antibody or therapeutic peptide can only be turned into an effective and marketable drug if formulated in such a way that it reaches the blood stream and is bioavailable.
But, while this characteristic - bioavailability - has been the focus of lab scientists, clinical researchers and process developers’ efforts for many years, finding the solution that gives a particular drug the desired profile is still a major headache for pharmaceutical firms.
Similarly, biopharmaceutical firms hoping to develop oral delivery alternatives for injectable biologics will also need to work out how to ensure that their products are bioavailable, safe and effective.
Our virtual event will bring together expert regulators, academics and the drug industry scientists to define the challenges and share the latest research breakthroughs to help you make the decisions that will let you overcome your Bioavailability Challenge.